Reset filter
Keywords
Blærekreft ×
Mostra di più Keywords
Sommario
  1. 1. Test clinico
  2. 2. Documentazione di routine
  3. 3. Registro / studio di coorte
  4. 4. Garanzia di qualità
  5. 5. Dati Standard
  6. 6. Risultato segnalato dal paziente
  7. 7. Specialità mediche
Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

78 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Bladder Cancer NCT01224665 - Pre-Randomization Off-Study Form Bladder Cancer #52060 S1011 NCT01224665

- 24/03/15 - 1 modulo, 5 itemgroups, 24 elementi, 1 linguaggio
Itemgroups: Header Module, Treatment Information, Off Treatment Reason, Additional Treatment, Vital Status
S1011 Pre-Randomization Off-Study Form (#52060) Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer NCT01224665 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9399F2B7-7E68-06C0-E040-BB89AD436952

dbGaP phs000346 Cancer Genetic Markers of Susceptibility for Bladder Cancer (CGEMS Bladder) - pht002184.v2.p2

- 12/10/22 - 5 moduli, 1 ItemGroup, 3 elementi, 1 linguaggio
ItemGroup: pht002184
Principal Investigator: Nathaniel Rothman, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MD, USA MeSH: Urinary Bladder Neoplasms,Carcinoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000346 This study funded by the National Cancer Institute (NCI) involves conducting a genome-wide association study of common genetic variants to identify markers of susceptibility to bladder cancer. This bladder GWAS has led to the discovery of three novel regions in the genome associated with bladder cancer risk. Cases were defined as individuals having histologically confirmed primary carcinoma of the urinary bladder, including carcinoma in situ (ICD-0-2 topography codes C67.0-C67.9 or ICD9 codes 188.1-188.9). Scan data were obtained from two case-control studies carried out in Spain and the United States (specifically, those in the Maine and Vermont components of the New England Bladder Cancer Study) and three prospective cohort studies in Finland and the United States (specifically Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, and The American Cancer Society Cancer Prevention Study II Nutrition Cohort). We used data from 591,637 single nucleotide polymorphisms 3,532 affected individuals (cases) and 5,119 controls of European descent and replication including 8382 cases and 48275 controls from 16 studies. In a combined analysis, we identified three new regions associated with bladder cancer on chromosomes 22q13.1, 19q12 and 2q37.1: rs1014971, (P ≈ 8 x 10sup-12/sup) maps to a non-genic region of chromosome 22q13.1, rs8102137 (P = 2 x 10sup-11/sup) on maps to CCNE1 and rs11892031 (P = 1 x 10sup-7/sup) maps to the UGT1A cluster on 2q37.1. We confirmed four previously identified genome-wide associations on chromosomes 3q28, 4p16.3, 8q24.21 and 8q24.3 (Rothman N et al., Nature Genetics, 2010, PMID: 20972438). Through meta-analysis with the MD Anderson Texas Bladder Cancer Study (TXBCS), we also identified a novel susceptibility locus that mapped to a region of 18q12.3, marked by rs7238033 (P = 8.7 x 10(-9); allelic odds ratio 1.20 with 95% CI: 1.13-1.28) and two highly correlated SNPs, rs10775480/rs10853535 (r(2)= 1.00; P = 8.9 x 10(-9); allelic odds ratio 1.16 with 95% CI: 1.10-1.22) (Garcia-Closas M et al, Human Molecular Genetics, 2011) For NCI-GWAS2, we performed genotyping on cases and controls for the New Hampshire component of the New England Bladder Cancer Study (NEBCS-NH). For the majority of new bladder cancer cases, we genotyped only cases from four case-control studies, the Los Angeles Bladder Cancer Study (LABCS), the French Center for Research on Prostate Diseases (CeRePP), the French Bladder Study (FBCS) and the Brescia Bladder Cancer Study (BBCS). We used existing control data from four cohort studies already genotyped and subjected to rigorous quality control metrics: the European Prospective Investigation Into Cancer and Nutrition Study (EPIC), Womens Health Initiative (WHI), Health Professionals Follow-up Study (HPFS), Nurses Health Study (NHS), which have been a part of Cancer Genetic Markers of Susceptibility (CGEMS). Meta-analysis of NCI-GWAS1, NCI-GWAS2 and a previously reported GWAS TXBCS-GWAS along with taqman replication, identified two new loci: rs10936599 on 3q26.2 (P = 4.53 x 10(-9)) and rs907611 on 11p15.5 (P = 4.11 x 10(-8)). Two notable loci were also identified that approached genome-wide statistical significance: rs6104690 on 20p12.2 (P = 7.13 x 10(-7)) and rs4510656 on 6p22.3 (P = 6.98 X 10(-7)); these require further studies for confirmation (Figueroa J et al, Human Molecular Genetics, 2013).

pht002185.v2.p2

1 ItemGroup 4 elementi

pht004007.v1.p2

1 ItemGroup 4 elementi

Eligibility

1 ItemGroup 1 elemento

pht002183.v2.p2

1 ItemGroup 3 elementi

Swedish Bladder Cancer Registry - Cystectomy - Follow-Up

- 27/09/21 - 1 modulo, 5 itemgroups, 106 elementi, 2 lingue
Itemgroups: General Information, Preoperative Data, Perioperative Data, Postoperative Data, Complications and Reoperations
Swedish Bladder Cancer Registry Healthcare Quality http://www.cancercentrum.se/vast/cancerdiagnoser/urinvagar/urinblase--och-urinvagscancer/kvalitetsregister/dokument/ Cystectomy - Follow-Up

Eligibility Bladder Cancer NCT01954173

- 18/08/19 - 1 modulo, 2 itemgroups, 16 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Adjuvant Radiation for High Risk Bladder Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01954173

Swedish Bladder Cancer Registry - 5-Year Follow-Up

- 19/11/17 - 1 modulo, 2 itemgroups, 15 elementi, 2 lingue
Itemgroups: General Information, Follow-Up
Swedish Bladder Cancer Registry Healthcare Quality http://www.cancercentrum.se/vast/cancerdiagnoser/urinvagar/urinblase--och-urinvagscancer/kvalitetsregister/dokument/ 5-year Follow-Up

Swedish Bladder Cancer Registry - Treatment of Primary Tumor

- 15/11/17 - 1 modulo, 2 itemgroups, 30 elementi, 2 lingue
Itemgroups: General Information, Treatment of Primary Tumor
Swedish Bladder Cancer Registry Healthcare Quality http://www.cancercentrum.se/vast/cancerdiagnoser/urinvagar/urinblase--och-urinvagscancer/kvalitetsregister/dokument/ Treatment of Primary Tumor

Swedish Bladder Cancer Registry - Registry

- 15/11/17 - 1 modulo, 2 itemgroups, 27 elementi, 2 lingue
Itemgroups: Registry, Tasks for Primary Diagnosis
Swedish Bladder Cancer Registry Healthcare Quality http://www.cancercentrum.se/vast/cancerdiagnoser/urinvagar/urinblase--och-urinvagscancer/kvalitetsregister/dokument/ Registry

Eligibility Bladder Cancer NCT00389155

- 04/10/17 - 1 modulo, 2 itemgroups, 12 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00389155

Eligibility DRKS00004052 NCT00661609 Bladder Cancer - Eligibility Advanced Bladder Cancer NCT00661609

- 17/09/21 - 1 modulo, 2 itemgroups, 8 elementi, 1 linguaggio
Itemgroups: Inclusion criteria, Exclusion criteria
Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) See http://clinicaltrials.gov/ct2/show/record/NCT00661609

Bladder Cancer NCT00014534 Follow-Up - CALGB: 90104 New Primary Cancer Form - 2169482v3.0 - CALGB: 90104 New Primary Cancer Form

- 09/01/15 - 1 modulo, 1 ItemGroup, 16 elementi, 1 linguaggio
ItemGroup: CCRR MODULE
CALGB: 90104 New Primary Cancer Form Combination Chemotherapy in Treating Patients With Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BE1B57B8-FFB5-70FA-E034-0003BA12F5E7

Bladder Cancer CALGB 90104 NCT00014534 - Chemotherapy Dose Form Bladder Cancer (CALGB 90104)

- 25/07/15 - 1 modulo, 1 ItemGroup, 26 elementi, 1 linguaggio
ItemGroup: Chemotherapy Dose Form
CALGB: 90104 Chemotherapy Dose Form Combination Chemotherapy in Treating Patients With Bladder Cancer NCT00014534 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BE1C0B11-7B76-737C-E034-0003BA12F5E7

Eligibility DRKS00010322 NCT00246974 Bladder Cancer - Eligibility

- 11/12/13 - 1 modulo, 2 itemgroups, 7 elementi, 2 lingue
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00246974

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial